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claudication (IC), CHD, and stroke were recorded. ABI< 0.9 was considered equivalent to
moderate-to-high CHD risk (10%).
Results: ABI< 0.9prevalencewas4.5%.Only0.62%presented lowABI and IC.Age, current smoker,
cardiovascular disease, anduncontrolledhypertension independently associatedwithABI< 0.9 in
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306 R. Ramos et al.of cardiovascular disease, 6.1% showed moderate-to-high 10-year CHD risk; adding ABI measure-
ment yielded 8.7%. Conversely, the risk function identified 16.8% of these participants as having
10-year CHD risk> 10%. In participants 75e79 free of cardiovascular disease, the prevalence of
ABI< 0.9 (i.e., CHD risk 10%) was 11.9%.
Conclusions: ABI< 0.9 is relatively frequent in those 35e79, particularly over 74.However, IC and
CHD risk 10% indicators areoftenmissing. Adding ABImeasurement toCHD-risk screening better
identifies moderate-to-high cardiovascular risk patients.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Primary prevention of cardiovascular diseases, a major
public health challenge in developed and developing
countries,1 is guided by risk estimation using mathematical
algorithms.2 However, risk functions fail to identify many
individuals who will develop a cardiovascular event within
10 years.3 As a complement to risk estimation, some
strategies, including diagnosing pre-symptomatic athero-
sclerosis, can improve detection of high-risk patients.1
The population prevalence of peripheral arterial disease
(PAD), the atherosclerotic occlusive disease of arteries
distal to the aortic bifurcation, ranges from 6.9% to 21.4%
depending on PAD definition, sex, and age range in western
countries.4e8 PAD risk factors are common to other
atherosclerotic diseases,9 and PAD indicates high risk of
coronary heart disease (CHD), stroke, and mortality irre-
spective of intermittent claudication (IC).10e14 PAD is
typically asymptomatic before progressing to clinical stages
ranging from IC to critical limb ischemia.10,11 Ankle-brachial
index (ABI) is a simple, inexpensive, and non-invasive PAD
measurement,15 even at the pre-symptomatic phase when
intervention can improve prognosis and prevent or delay
severe complications.16,17 Sensitivity and specificity of a 0.9
ABI cut-off value are w95% for detecting angiographically
positive PAD in symptomatic individuals.16e19
These characteristics imply the equivalent of high
cardiovascular risk, suggesting that ABI can offer additional
information about a patient’s cardiovascular risk. Cardio-
vascular prevention programs could include ABI measure-
ment for PAD screening.5 The study aimed to determine the
prevalence of ABI< 0.9 and of symptomatic PAD, their
association with cardiovascular risk factors, and the impact
on identifying otherwise undetected moderate-to-high-risk
individuals if ABI measurement were added to population
screening for CHD risk.
Methods
Population
This population-based cross-sectional study was conducted
between 2005 and 2006 in Girona province (w600,000
inhabitants), northeastern Spain.20
We selected a random population sample of participants
aged 35e79 years from the city of Girona (w70,000
inhabitants) and two rural towns, stratified by age and sex.
Although sample size was calculated for a cross-sectional
risk factor prevalence study,21 with a prevalence of low ABI
of 5.2% and 3.9% for men and women, respectively, ourcomparisons in men and women were powered at 80% to
detect as statistically significant (p-value< 0.05) differ-
ences between low and normal ABI participants of at least
12% units in a categorical variable, with a point estimate of
50% (most conservative approach).
All participants were duly informed and signed their
consent to participate in the study, approved by the local
ethics committee.
Measurements
Examinations were performed by trained nurses and inter-
viewers using standard questionnaires and measurement
methods.22
Body mass index (BMI) was calculated as weight divided
by squared height (kg/m2).
Blood pressure was measured with a calibrated oscillo-
metric sphygmomanometer (OMRON 705 IT) using a cuff
adapted to upper arm perimeter (young, adult, obese).
After 5 min rest, two measurements were taken, at least
20 min apart, and the lower value recorded. Participants
were considered hypertensive if previously diagnosed
by a physician, under treatment, or presenting systolic
blood pressure (SBP) 140 or diastolic blood pressure
(DBP) 90 mmHg. Uncontrolled hypertension was defined
as SBP 140 or DBP 90 mmHg (130/80 mmHg in partici-
pants with diabetes).
Blood was drawn after 10e14 h fasting, with >60 s of
venostasis. Methods and quality control of determination of
total cholesterol, HDL-c and triglyceride concentrations are
detailed elsewhere.21
Diabetes was defined as history of diabetes, diabetes
treatment or fasting glycemia> 125 mg/dl.
CHD risk was calculated in all participants 35e74 years
old and free of cardiovascular disease using the Framing-
ham function adapted to Spain and validated in this pop-
ulation. In summary, this methodology maintains the
original model structure (including variables) and the orig-
inal b-coefficients but substitutes local incidence and risk
factor prevalence for the Framingham coronary event
incidence rate and risk factor prevalence. This function has
been shown to accurately and reliably predict CHD risk for
patients aged 35e74.23,24
A standardized smoking questionnaire was used to
evaluate cigarette consumption.22 Participants were clas-
sified as smokers (current or quit< 1 year), former
smokers (quit 1 year) or never smokers. In the multi-
variate analysis, former smokers and never smokers were
considered non-current smokers in a dichotomized
variable.
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angina, or stroke) was considered when diagnosed by
a physician. Primary care and hospital clinical records of all
participants were reviewed for history of arterial limb
revascularization procedures.
ABI measurement
After a 5-min rest, systolic bloodpressurewasmeasured in the
brachial artery in the antecubital fossa in both arms, with
a continuous Doppler device (SONICAID 421, Oxford Instru-
ments), 8 MHz probe. The cuff was then applied to the distal
calf, and the Doppler probe was used to determine systolic
blood pressure in supineposition at the right and left posterior
and anterior tibial arteries. Right and left ABI were calculated
as the ratio of thehighest of the two systolicpressures in lower
limbs (posterior and anterior tibial arteries) to the average of
the right and left brachial systolic pressures, unless there was
a discrepancy 10 mmHg between the two arms (in which
case the highest reading was used). The lower of the two ABI
values obtained from the left and the right ankle was used for
analysis. ABI< 0.9 in either leg was considered moderate-to-
high cardiovascular risk 5,10e15; ABIs in the 0.9e1.39 range
were considered normal; ABI> 1.39 was excluded from eval-
uation since the possible influence of arterial wall stiffness
made it impossible to discard arterial obstruction.13,25 Oper-
ators were meticulously trained by a senior vascular surgeon.
A protocol of independent measurements assessed operator
performance and found low inter- and intra-operator vari-
ability, showing an intraclass correlation coefficient of 0.92
and 0.94, respectively.
Edinburgh questionnaire
Claudication was assessed using participants’ answers (as
noted) to the Edinburgh questionnaire26:
1. Do you get any pain or discomfort in your legs when you
walk? (Yes)
2. Does this pain ever occur when you are standing still or
sitting? (No)
3. Do you get this pain if you walk uphill or hurry? (Yes)
4. Do you get this pain if you walk at an ordinary pace on
level ground? (NoZmild, YesZmoderate/severe)
5. What happens to the pain if you stand still? (It goes away)
6. Does the pain disappear within 10 min or less when you
stand still (Yes)
7. Where do you get the pain or discomfort? (leg diagram
is presented to patient)
Based on the conditions fulfilled by the response,
patients were classified as follows:
1) Definite claudication
- All responses to questions 1e6 as noted above
- Calf areamarked on the diagramof the leg (question 7)
2) Atypical claudication
- All responses to questions 1e6 as noted above
- Thigh or buttock marked on the diagram of the leg, in
the absence of calf pain (question 7)
3) No claudication. Any other combination of responsesPAD was considered asymptomatic when ABI< 0.9 and
the Edinburgh questionnaire showed no IC. Symptomatic
PAD included patients with ABI< 0.9 and definite or atyp-
ical IC based on the Edinburgh questionnaire.
Statistical analysis
Prevalence is presented by sex and is standardized for age
according to the age distribution of the standard world pop-
ulation.27 Continuous variables are presented as mean and
standard deviation or median and interquartile range when
their distribution departs from normal (glycemia, triglycer-
ides). KruskalleWallis or Student’s t-test was used for
differences in continuous variables and Chi square tests for
categorical variables. Adjusted odds ratios (OR) of ABI< 0.9
were estimated by a logistic model for demographic,
comorbidity, clinical and severity variables that showed
significant differences (p< 0.05) in the univariate analysis.
Important variables based on clinical judgment, such as age,
sex or diabetes,were also included as potential confounders.
Results
From a randomly selected population sample of 8485
eligible subjects aged 35e79 years, 6262 (73.8%) agreed to
participate. The response rate did not vary substantially by
age and sex groups. Therefore, it is reasonable to suppose
that age and gender selection bias is minimized. Analysis
included 2903 men and 3269 women (nZ 6172); 78
participants with ABI> 1.39, suggesting arterial wall stiff-
ness, and 12 participants without ABI measurement were
excluded.
Table 1 shows participant characteristics, comparing the
presence of cardiovascular risk factors by sex in the total
population sample aged 35e79. Table 2 shows prevalence
of ABI< 0.9 with symptomatic PAD by sex and age groups.
ABI< 0.9 was present in 277 participants (4.5%, 95%CI:
4.0e5.0%), 150 men (5.2%, 95%CI: 4.4e6.0%) and 127
women (3.9%, 95%CI: 3.2e4.6%). Only 0.62% (95%CI:
0.44e0.84%) with low ABI presented IC as assessed by the
Edinburgh questionnaire (13.7% (95%CI: 9.9e18.3%) of all
participants with ABI< 0.9). Age-standardized prevalence
of ABI< 0.9 was 4.23 (95%CI: 3.57e4.89) in men and 3.75
(95%CI: 3.10e4.41) in women.
Prevalence of ABI< 0.9 was highest in participants
75e79 years old (14.1%, 95%CI: 11.3e17.3%). Prevalence of
ABI< 0.9 in those individuals 75e79 years old free of known
vascular disease was 11.9% (95%CI: 9.1e15.3%).
Low-ABI participants were older and more often dia-
betic, hypertensive, and, in men, current smokers.
Myocardial infarction, angina, and stroke were significantly
more prevalent in ABI< 0.9 individuals, along with higher
10-year CHD risk in the 35e74 age group for whom this risk
function is calibrated. Table 3 compares cardiovascular risk
factors in individuals with and without ABI< 0.9, by sex.
ABI< 0.9 was independently and positively associated in
the study population with age, current smoker, cardiovas-
cular disease, and uncontrolled hypertension, and also with
IC in men and diabetes in women (Table 4).
From the 6172 included individuals, CHD risk was
calculated in all participants 35e74 years old and free of
Table 1 Comparison of presence of cardiovascular risk factors by sex in a population sample aged 35e79 years in Girona, Spain
Men Women p-Value
N 2903 3269
Agea 56.6 (12.3) 55.9 (12.3) 0.029
Hypertension 50.6% 41.1% <0.001
Diabetes 18.6% 11.9% <0.001
Smoking
Current or former smoker 1 year 29.6% 15.9% <0.001
Former smoker >1 year 41.2% 12.8% <0.001
Never smoker (%) 29.1% 71.3% <0.001
Systolic blood pressurea 131 (18) 125 (21) <0.001
Diastolic blood pressurea 80 (10) 77 (10) <0.001
Uncontrolled hypertension 36.4% 26.7% <0.001
Total cholesterola 209 (40) 213 (43) <0.001
HDL cholesterola 47 (12) 57 (14) <0.001
LDL cholesterola 136 (36) 135 (37) 0.103
Triglyceridesb 104 (78e144) 86 (64e120) <0.001
Body mass indexa 27.8 (3.8) 27.0 (5.1) <0.001
10-year CVD risk< 10%c 87.6% 98.4% <0.001
History of arterial limb revascularization 0.34% 0.00% 0.001
Any cardiovascular disease 8.32% 4.02% <0.001
ABI< 0.9 5.17% 3.88% 0.015
ABI< 0.9 and Edinburgh definite or atypical 1.17% 0.12% <0.001
ABI< 0.9 and Edinburgh normal 3.92% 3.74% 0.712
CVD: cardiovascular disease. HDL: high density lipoproteins. LDL: low density lipoproteins. Edinburgh: Edinburgh intermittent claudi-
cation questionnaire.
a Mean (Standard deviation).
b Median (1st quartilee3rd quartile).
c Calculated for CVD-free participants aged 35e74 years free of cardiovascular disease.
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Framingham CHD-risk functions), for a total of 5228
participants who fulfilled this condition. Mean 10-year CHD
risk in the subgroup of 161 patients with ABI< 0.9 was 9.2%
in men and 3.0% in women. Only 1.9% (95%CI: 0.4e5.3%) of
participants with ABI< 0.9 presented CHD risk 20%; in
16.8% (95%CI: 11.4e23.5%) it was 10% (Fig. 1). Although
ABI and 10-year CHD risk were significantly and inversely
correlated in participants aged 35e74 and free ofTable 2 Prevalence of ankle-brachial index less than 0.9 by se
Girona, Spain
Men
d/n ABI< 0.9
Ages groups
35e44 years 7/607 1.2%
45e54 years 8/709 1.1%
55e64 years 27/719 3.8%
65e74 years 60/599 10.0%
75e79 years 48/269 17.8%
All 150/2903 5.2%
All age standardized
by world population
150/2903 4.2%
ABI< 0.9 and Edinburgh
definite or atypical
34/2903 1.2%
ABI< 0.9 and Edinburgh normal 116/2903 4.0%
d: Diagnosed ABI< 0.9; n: number of participants; ABI: ankle-brachiacardiovascular disease, the Spearman correlation was
modest: 0.15 (p< 0.001) in men and 0.11 (p< 0.001) in
women. Among participants with ABI< 0.9, this coefficient
increased to 0.37.
Combining CHD-risk estimation with ABI measurement
changed the proportion of participants aged 35e74 years
with moderate-to-high (10%) CHD risk from 6.1% (95%CI:
5.5e6.8%) to 8.7% (95%CI: 7.9e9.5%), a change of 11.4 to
13.5% in men, and 1.6 to 4.6% in women.x and age groups in a population sample aged 35e79 years in
Women
95% CI d/n ABI< 0.9 95% CI
(0.5%; 2.4%) 25/730 3.4% (2.2%; 5.0%)
(0.5%; 2.2%) 18/841 2.1% (1.3%; 3.4%)
(2.5%; 5.4%) 24/768 3.1% (2.0%; 4.6%)
(7.7%; 12.7%) 30/646 4.6% (3.2%; 6.6%)
(13.5%; 23.0%) 30/284 10.6% (7.2%; 14.7%)
(4.4%; 6.0%) 127/3269 3.9% (3.2%; 4.6%)
(3.6%; 4.9%) 127/3269 3.8% (3.1%; 4.4%)
(0.8%; 1.6%) 4/3269 0.1% (0.0%; 0.3%)
(3.3%; 4.8%) 123/3269 3.8% (3.1%; 4.5%)
l index; CI: Confidence interval.
Table 3 Comparison of presence of cardiovascular risk factors between individuals with and without ankle-brachial
index< 0.9 in men and women aged 35e79 years
Men Women
ABI< 0.9 ABI 0.9 p ABI< 0.9 ABI 0.9 p
N 150 2753 127 3142
Agea 68.2 (10.0) 56.0 (12.1) <0.001 61.0 (14.0) 55.7 (12.2) <0.001
Hypertension 72.0% 49.5% <0.001 58.3% 40.4% <0.001
Diabetes 28.7% 18.0% 0.001 22.8% 11.5% <0.001
Smoking
Current or former
smoker 1 year
31.3% 29.5% <0.001 16.0% 15.9% 0.154
Former smoker >1 year 57.3% 40.4% <0.001 7.20% 13.0% 0.154
Never smoker 11.3% 30.1% <0.001 76.8% 71.1% 0.154
Systolic blood pressurea 139 (19) 130 (18) <0.001 137 (27) 124 (20) <0.001
Diastolic blood pressurea 78 (11) 81 (10) 0.009 79 (11) 77 (10) 0.057
Uncontrolled hypertension 58.0% 35.2% <0.001 45.7% 25.9% <0.001
Total cholesterola 202 (43.5) 209(39.8) 0.035 216 (49) 213 (43) 0.423
HDL cholesterola 47 (14) 47 (12) 0.679 57 (17) 57 (14) 0.782
LDL cholesterola 128 (37) 137 (36) 0.003 132 (37) 135 (37) 0.442
Triglyceridesb 107 (80e142) 103 (78e144) 0.520 91 (71e123) 86 (64e120) 0.194
Body mass indexa 27.7 (3.8) 27.8 (3.8) 0.962 26.5 (5.0) 27.0 (5.1) 0.293
10-year CVD risk< 10%c 65.3% 88.3% <0.001 96.5% 98.4% 0.163
Cardiovascular disease 26.8% 7.32% <0.001 16.5% 3.51% <0.001
Edinburgh definite
or atypical
22.7% 3.49% <0.001 3.15% 3.34% 1.000
ABI: ankle-brachial index. CVD: cardiovascular disease. HDL: high density lipoproteins. LDL: low density lipoproteins. Edinburgh:
Edinburgh intermittent claudication questionnaire.
a Mean (Standard deviation).
b Median (1st quartilee3rd quartile).
c Calculated for CVD-free participants aged 35e74 years.
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Although most classical CHD-risk factors were associated to
PAD, less than 20% of those 35e74 years old and free of CHD
with ABI< 0.9 were at 10% 10-year CHD risk. Including
ABI< 0.9 in the screening process results in a considerableTable 4 Adjusted odds ratios and 95% confidence interval
for factors independently related to ankle brachial
index< 0.9 in participants aged 35e79 years
Variable Odds ratio 95% CI
Men
Age (1 year) 1.09 1.07 1.11
Current smoker 2.14 1.43 3.21
Cardiovascular disease 2.13 1.38 3.28
Edinburgh definite or atypical 5.22 3.25 8.38
Uncontrolled hypertension 1.52 1.06 2.19
Women
Age (1 year) 1.02 1.01 1.04
Current smoker 1.89 1.10 3.24
Cardiovascular disease 3.26 1.88 5.68
Diabetes 1.59 1.00 2.51
Uncontrolled hypertension 1.74 1.16 2.61
CI: confidence interval. Edinburgh: Edinburgh intermittent
claudication questionnaire.increase in the proportion of moderate-to-high-risk pop-
ulation when combined with 10-year CHD risk 10% by risk
functions. Many participants aged 75e79, not amenable to
CHD-risk function calculations, presented ABI< 0.9 (i.e.,
symptomatic or asymptomatic PAD) and could be consid-
ered at high risk.5,10e15 Furthermore, the Edinburgh ques-
tionnaire revealed IC symptoms in only a modest portion of
participants with ABI< 0.9. Therefore, our results support
the idea that cardiovascular risk screening strategies could
be improved by adding ABI measurement, particularly for
those beyond age 74. These findings concur with recently
published data13 of countries with high incidence of CHD.
Our study confirms this data in a Mediterranean population
with a known low risk of CHD.
Age, smoking, hypertension and diabetes mellitus are the
cardiovascular risk factors most often associated with
PAD.4,9,16 In our study, although diabetes was more preva-
lent in the PAD group in both sexes, it independently asso-
ciated with PAD only in women. This finding is consistent
with the more deleterious effect of diabetes on CHD
development observed in women.28 Uncontrolled hyper-
tension was independently associated with low ABI in both
sexes, displacing hypertension in the multivariate model.
Presence of IC was significantly related to ABI< 0.9 in
men. Male sex increased the risk of a symptomatic
obstruction; asymptomatic PAD prevalence was similar in
both sexes (Table 2). This suggests that atherosclerotic
obstruction progresses faster in men who present a worse
Figure 1 Distribution of 10-year coronary heart disease risk
estimation in participants aged 35e74 years free of cardio-
vascular disease with ankle-brachial index< 0.9.
310 R. Ramos et al.cardiovascular risk profile, particularly smoking, which is
consistent with the higher arterial limb revascularization
rate observed in men. The low prevalence of individuals
with ABI< 0.9 and IC indicates that PAD can only be
comprehensively diagnosed by systematic screening that
includes ABI measurement.
The prevalence of ABI< 0.9 in our study was similar to
that described elsewhere,12,29,30 slightly lower than in
northern Europe.4,6 The large variability in reported PAD
prevalence is probably due to differing definitions of PAD and
participant inclusion criteria, particularly age ranges.4e8
Indeed, age is of particular interest in our study. Our
findings show that the prevalence of PAD, as defined by
ABI< 0.9, is relatively high in the 35 to 79-year-old pop-
ulation in Spain; almost 14.1% of the population aged 75e79
presented some stage of this disease. The crude prevalence
of ABI< 0.9 was higher in men than in women, with the
highest PAD prevalence in men observed in subjects older
than 65 years. Age-standardized prevalence canceled the
sex-based difference.
Implications of the study results
Systematic CHD-risk screening that combines ABI
measurement e a quick, easy, and low-cost technique to
diagnose inferior limb arterial obstruction with high sensi-
tivity and specificity16,18,19 e with 10-year CHD-risk func-
tions is supported by the considerable prevalence of
ABI< 0.9 in the 35e79 age group. In addition, diagnosing
asymptomatic PAD identifies individuals at increased risk of
suffering cardiovascular events10e16 despite an apparently
low 10-year CHD risk by risk functions. Information
provided by ABI measurement could be combined with
10-year CHD-risk estimation by CHD-risk functions, or
incorporated in future cardiovascular prediction functions.
The preventive effect of interventions in individuals withsymptomatic PAD is well known,31e34 and it is likely that
these interventions have beneficial effects of early risk
factor modification and medication (e.g., anti-platelet
drugs and statins) in subjects with subclinical disease.
However, this likelihood remains to be ascertained in
future clinical trials. Cost-effectiveness of ABI screening is
unknown. Our data show that some 48 (100/2.1) men have
to be screened with ABI to detect 1 more subject with an
elevated risk of CHD, and some 33 (100/3) women. Current
knowledge supports the international consensus criteria
for PAD screening,15,16 but more studies are needed to
determine whether adding the ABI measurement in
a screening strategy would be cost-effective and feasible
in the general population.
Study characteristics
The sample size and high participation rate (w74%) yield
adequate statistical power and guarantee external validity
and representativeness of the studied population.
However, the cross-sectional nature of the study and the
age range (35e79 years) may be considered potential
limitations to the observed associations and to the gener-
alizability of our findings. We chose to extend the screening
age range down to 35 years to test the magnitude of
prevention achievable with early primary prevention in
younger subjects, which was unknown in Spain.
In conclusion, we found ABI< 0.9 to be associated with
most classical CHD-risk factors, as expected, but also
relatively frequent in the population aged 35e79 (and
particularly those aged 74e79) with no claudication symp-
toms and an apparent 10-year coronary risk< 10%, based on
CHD-risk functions. Incorporating systematic ABI measure-
ment into screening for CHD risk may improve cardiovas-
cular risk stratification and increase early identification of
patients with moderate-to-high cardiovascular risk,
particularly in those beyond the age range for which risk
functions were established.
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